Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
COSMIC-313: Adding cabozantinib to nivo-ipi may improve PFS in advanced RCC
The combination of nivolumab, ipilimumab, and cabozantinib improved progression-free survival (PFS) in patients with previously untreated, advanced renal cell carcinoma (RCC) of intermediate or poor risk as per IMDC* criteria, results of the phase III COSMIC-313 trial showed.
COSMIC-313: Adding cabozantinib to nivo-ipi may improve PFS in advanced RCC
04 Nov 2022
NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC
Adding nivolumab to paclitaxel-carboplatin chemotherapy in the neoadjuvant setting boosted progression-free survival (PFS) and overall survival (OS) in patients with resectable stage IIIA–B non-small cell lung cancer (NSCLC), according to results of the phase II NADIM II trial from Spain.
NADIM II suggests PFS, OS benefits of nivolumab + chemo in resectable NSCLC
02 Nov 2022
Real-world data affirms palbociclib–AI combo efficacy in metastatic breast cancer
The use of the combination of palbociclib plus an aromatase inhibitor (AI) in the first-line treatment setting appears to confer survival advantage on patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) metastatic breast cancer (MBC), according to real-world data.
Real-world data affirms palbociclib–AI combo efficacy in metastatic breast cancer
30 Oct 2022
Cemiplimab shows favourable signals as first-, second-line treatment alternative for NSCLC
In the 3-year follow-up of the EMPOWER-Lung 1 study, first-line cemiplimab continued to outdo chemotherapy (CT) in providing survival benefit for patients with advanced non-small-cell lung cancer (NSCLC). Moreover, in the second-line setting (patients with progressive disease [PD]), cemiplimab added to CT provided meaningful and durable objective response rate (ORR) and overall survival (OS) benefit.